Kestra Medical Technologies (NASDAQ:KMTS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kestra Medical Technologies (NASDAQ:KMTS) from a sell rating to a hold rating in a report released on Saturday.

A number of other brokerages have also recently commented on KMTS. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Finally, BTIG Research raised their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus price target of $27.83.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ:KMTS opened at $26.40 on Friday. The business’s 50 day moving average price is $22.96 and its 200-day moving average price is $22.57. Kestra Medical Technologies has a 1 year low of $14.30 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The firm has a market capitalization of $1.55 billion, a PE ratio of -10.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. As a group, equities research analysts expect that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Timothy P. Moran sold 2,380 shares of Kestra Medical Technologies stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.76, for a total transaction of $56,548.80. Following the transaction, the insider owned 66,345 shares in the company, valued at $1,576,357.20. The trade was a 3.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alfred J. Ford, Jr. sold 6,275 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.09, for a total transaction of $151,164.75. Following the transaction, the insider directly owned 99,564 shares in the company, valued at approximately $2,398,496.76. The trade was a 5.93% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 211,877 shares of company stock worth $4,922,844. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Kestra Medical Technologies

Several hedge funds have recently made changes to their positions in KMTS. Seven Grand Managers LLC purchased a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at approximately $2,652,000. Eventide Asset Management LLC grew its position in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the period. Sei Investments Co. increased its stake in Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in Kestra Medical Technologies during the fourth quarter worth $9,282,000. Finally, UBS Group AG raised its position in Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after purchasing an additional 69,908 shares during the period.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.